Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
- 17 June 2009
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 121 (1) , 1-11
Abstract
Although the androgen receptor (AR) is a known clinical target in prostate cancer, little is known about its possible role in breast cancer. We have investigated the role of AR expression in human breast cancer in response to treatment with the antiestrogen tamoxifen. Resistance to tamoxifen is a major problem in treating women with breast cancer. By gene expression profiling, we found elevated AR and reduced estrogen receptor (ER) α mRNA in tamoxifen-resistant tumors. Exogenous overexpression of AR rendered ERα-positive MCF-7 breast cancer cells resistant to the growth-inhibitory effects of tamoxifen in anchorage-independent growth assays and in xenograft studies in athymic nude mice. AR-overexpressing cells remained sensitive to growth stimulation with dihydrotestosterone. Treatment with the AR antagonist Casodex™ (bicalutamide) reversed this resistance, demonstrating the involvement of AR signaling in tamoxifen resistance. In AR-overexpressing cells, tamoxifen induced transcriptional activation by ERα that could be blocked by Casodex, suggesting that AR overexpression enhances tamoxifen’s agonistic properties. Our data suggest a role for AR overexpression as a novel mechanism of hormone resistance, so that AR may offer a new clinical therapeutic target in human breast cancers.Keywords
This publication has 47 references indexed in Scilit:
- A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancerGenes & Development, 2006
- Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast CancerThe Oncologist, 2006
- Elevated Expression of Mitogen-Activated Protein Kinase Phosphatase 3 in Breast Tumors: A Mechanism of Tamoxifen ResistanceCancer Research, 2006
- Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cellsMolecular Cancer Therapeutics, 2006
- Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone AcetateCancer Research, 2005
- Impact of metastatic estrogen receptor and progesterone receptor status on survivalBreast Cancer Research and Treatment, 2005
- Profiling of Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell PhenotypeEndocrinology, 2003
- Androgens induce divergent proliferative responses in human breast cancer cell linesThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)European Journal of Cancer, 1993